Proposal to widen access to treatments for juvenile idiopathic arthritis NZNO welcomes your feedback on PHARMAC’s proposal to widen access to three funded treatments, adalimumab, etanercept and tocilizumab, for the treatment of juvenile idiopathic arthritis (JIA). This is an inflammatory condition that affects the joints of children and young people. Access criteria for adalimumab and etanercept would be widened to include funding for treatment of oligoarticular course JIA and treatment of polyarticular course JIA affecting 5 or more joints. Access criteria for tocilizumab would be widened for polyarticular course JIA affecting 5 or more joints at the same time. Further information on the consultation is available here. If no feedback is received, NZNO will not make a submission. Please send feedback to PolicyAnalysts@nzno.org.nz by 22 September 2020.